704.5000 -19.05 (-2.63%)
NSE Apr 30, 2025 15:31 PM
Volume: 14,765
 

ICICI Securities Limited
Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.
Tatva Chintan Pharma.. has an average target of 1130.50 from 2 brokers.
More from Tatva Chintan Pharma Chem Ltd.
Recommended